It wasn't easy to find the list of drugs whose prices are to be negotiated. Along with the others,
there is a present for the wives of many in Congress (Botox:-). That's what I thought - until I read
the small print and it seems that, despite the bill already moving across desks, there still isn't an
official list!
Here ya go:
[https://www.americanprogress.org/article/congress-can-act-no...](https://www.americanprogress.org/article/congress-can-act-now-to-lower-drug-costs-by-allowing-medicare-to-negotiate-prices/)
Some drugs could be subject to price negotiation under proposed reforms to lower prescription drug costs
Examples of Medicare Part B and Part D drugs that could be subject to negotiation, and spending and
utilization among Medicare beneficiaries, 2019
Medicare Part B
Drug name Therapeutic class Average spending per beneficiary Total
number of beneficiaries
Orencia (Bristol-Myers Squibb) Musculoskeletal $31,700 29,031
Cimzia (UCB) Gastrointestinal $24,097 18,231
Xolair (Genentech) Respiratory $22,345 17,911
Botox (Allergan) Neurologic $2,510 146,030
Aranesp (Amgen) Oncologic $4,821 47,938
Tysabri (Biogen) Neurologic $43,123 5,142
Medicare Part D
Drug name Therapeutic class Average spending per beneficiary Total number of beneficiaries
Revlimid (Celgene) Oncologic $110,711 42,215
Xarelto (Janssen) Blood Agent $3,595 1,134,222
Januvia (Merck) Endocrine/diabetes $3,769 938,165
Lantus Solostar (Sanofi-Aventis) Endocrine/diabetes (insulin) $2,585 965,522
Symbicort (AstraZeneca) Respiratory $1,827 1,103,477
NovoLog FlexPen (Novo Nordisk) Endocrine/diabetes (insulin) $3,063 602,128
Levemir FlexTouch (Novo Nordisk) Endocrine/diabetes (insulin) $3,266 496,640
Victoza 3-Pak (Novo Nordisk) Endocrine/diabetes $6,141 248,675
Myrbetriq (Astellas) Genitourinary $2,558 564,887
Restasis (Allergan) Ophthalmologic $2,405 563,545
Spiriva (Boehringer Ingelheim) Respiratory $2,799 455,668
Humalog KwikPen U-100 (Eli Lilly) Endocrine/diabetes (insulin) $2,775 438,914
Tradjenta (Boehringer Ingelheim) Endocrine/diabetes $3,530 336,435
Lantus (Sanofi-Aventis) Endocrine/diabetes (insulin) $2,746 422,031
Linzess (Allergan) Gastrointestinal $2,384 412,698
Xifaxan (Gilead) Infectious disease $8,594 88,695
Table: Center for American Progress Source: Centers for Medicare and Medicaid Services, "Medicare Part
B Spending by Drug," available at [https://data.cms.gov/summary-statistics-on-use-and-payments/...](https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-)
medicaid-spending-by-drug/medicare-part-b-spending-by-drug (last accessed January 2022); Centers for
Medicare and Medicaid Services, "Medicare Part D Spending by Drug," available at
[https://data.cms.gov/summary-statistics-on-use-and-payments/...](https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-)
part-d-spending-by-drug (last accessed January 2022). Therapeutic class information from SSR Health
(2021) was provided by third-party researchers and is on file with authors
Jeff